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specificity to T2w MRI (reduction of false-positive findings), 
but its main value lies in its direct correlation between the 
choline-to-citrate ratio and tumor aggressiveness.  
mpMRI currently more and more consists of T2w MRI 
combined with DWI. DCE is additionally performed in all 
cases by some institutions, or only in doubtful cases by 
others. Meanwhile, it remains very important that all mpMRI 
studies are performed according to uniform quality and 
reporting standards, as pointed out by the European Society 
of Urogenital Radiology Guidelines and the recently revised 
Prostate Imaging Reporting and Data System (PI-RADS version 
2). The latter consists of a diagnostic probability scale, in 
which PI-RADS 1 and 2 signify “clinically significant disease 
(highly) unlikely”, PI-RADS 3 “clinically significant disease is 
equivocal”, and PI-RADS 4 and 5 signify “clinically significant 
disease (highly) likely”. These scales are largely based on the 
unique ability of mpMRI to more easily detect high-grade and 
larger (i.e. clinically significant) tumors than small lower-
grade lesions. This holds promise in the assessment of 
patients suspected of having prostate cancer. In patients who 
are candidates for active surveillance on the basis of clinical 
parameters, a PI-RADS 1 or 2 scale can corroborate this 
choice owing to a negative predictive value for excluding 
high-grade disease up to 98%, while in patients with a PI-
RADS 4 or 5 a targeted biopsy can be performed in the 
suspicious area, including areas that are more difficult to 
reach with standard biopsy (e.g. anteriorly located tumors). 
PI-RADS 3, on the other hand, requires a biopsy in selected 
cases, taking into account clinical parameters such as PSA-
density, PSA-kinetics, patient age and potential comorbidity. 
Hence, the performance for correctly assigning patients to 
active surveillance can be increased and mpMRI is currently 
recommended at enrolment in active surveillance by the UK 
National Institute for Health and Care Excellence (NICE). 
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Prostate cancer (PCa) is the most common male malignancy. 
The number of diagnoses has increased since the introduction 
of the PSA in the early ‘90ies. Up to 50% of the new PCa 
detected can be considered clinically insignificant or 
indolent: this relatively new concept in oncology means that 
these very well localized, small and non aggressive tumors 
(GPS=3+3), which are generally diagnosed with a biopsy 
following PSA rises, would not cause symptoms and/or death 
during one’s life. Despite this non aggressive behavior, most 
of these tumors are still treated with curative standard 
therapies (prostatectomy, external radiotherapy and 
brachytherapy), which, although equally effective treatment 
options, are burdened by potentially severe side effects.  
As a matter of fact, there is no way to entirely distinguish 
upfront, before as well as after the biopsy, non aggressive, 
clinically insignificant, indolent tumors from aggressive, 
potentially lethal cancers that need to be treated 
immediately. To deal with the problem of overdiagnosis and 
overtreatment, active surveillance (AS) is being proposed in 
alternative to radical treatment to very selected men with 
favourable disease characteristics. AS is widely accepted in 
uro-oncologic communities and included in several 
guidelines, even if its routine application in the clinic is still 
suboptimal.  
Understanding the natural history of clinically insignificant 
PCa is of primary importance to obtain reliable tools to select 
and follow-up AS patients. AS inclusion criteria are presently 
based on ≤T2a at DRE, PSA/PSA density, number and 
percentage of positive biopy cores and GPS. Originally, the 
approach was more restrictive (i.e. selection of very low risk 
PCa patients). Nowadays, considering that feasibility and 
safety of these more strict protocols were assessed, more 
inclusive protocols are enrolling patients (e.g. including 
selected GPS=3+4).  
One of the main issues AS is currently facing is the chance of 
“inadequate” diagnoses from biopsies, known to result in 
upgrading and upstaging at prostatectomy, especially for low-
grade PCa. PSA/PSA density or the number of positive cores 
at diagnostic biopsy do not appear to be associated with the 
probability of upgrading patients initially fit for AS. This is 
the main reason to consider a confirmatory biopsy (time 
varying between 3 and 12 months) in most AS protocols, 
which can help identify patients ineligible for AS as a result 
of disease upgrading. The rate of “reclassification” at 
confirmatory biopsy varies between 16 and 30%, very similar 
to the one after prostatectomy.  
Due to its great potential, MRI is increasingly used, being able 
to identify lesions that might be missed by standard biopsy. A 
positive MRI is associated to higher upgrading rates after 
prostatectomy and also after confirmatory biopsy. At 
present, in men on AS, MRI is used as an aid to detect 
clinically significant disease and help target suspicious 
lesions; however, there is still no solid evidence to endorse 
MRI in place of repeated biopsies.  
Investigation on genetic/biomolecular/biochemical signatures 
is urgently needed to better classify our patients, trying to 
take benefit from non-invasive indicators of progression or 
reclassification. Research is currently focused on finding 
genetic signatures of both positive biopsy and adjacent 
normal tissue/stroma and on studying biomolecular markers 
possibly present in urine and blood (liquid biopsy). Recently, 
tests based on high expression of selected genes in biopsy 
specimens were found to be associated with higher risk of 
disease progression, but the possible true impact on AS is still 
to be determined.  
AS follow-up plays a crucial role, since it enables to monitor 
the tumor behavior and potentially detect the more 
aggressive forms, which may benefit from treatment. In most 
protocols, follow up is based on clinical data (DRE, PSA and 
repeat biopsies), some protocols recently including mpMRI. 
Biomarkers (e.g. PCA3 or -2proPSA) are not routinely used in 
AS protocols, due to confusing results coming from the 
literature.  
In conclusion, the results of AS programs should be primarily 
assessed on their ability to avoid overtreatment, while 
guaranteeing the same curability window of upfront radical 
treatments. The percentage of patients who remain 
treatment free is one of these measures, with current 
estimates being ≈40% at 20 years from diagnosis. Evaluation 
of oncological outcomes such as OS and CSS rates is also 
important, being in the Canadian AS cohort 62% and 94% at 15 
yrs, respectively. Secondary objectives should include 
quality-of-life and comparison of AS vs radical therapies 
costs. The variety of inclusion criteria and follow-up 
protocols makes the evaluation difficult. However, to date, 
the published outcomes are similar to those in patients 
receiving immediate curative treatment. 
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In the past 2-3 decades we have witnessed major advances of 
radiotherapy planning. These developments were based on 
implementation of sectional imaging, computerized 
treatment planning and high precision treatment 
technologies in the radiotherapy process. When compared 
with the conventional radiography based method, modern 3-4 
dimensional approaches require accurate and reproducible 
delineation of the target volume and organs at risk on the 
sectional images of various modalities, including computed 
tomography, magnetic resonance imaging, positron emission 
tomography and ultrasound. Contouring variation represents 
one of the most important contributors to the overall 
uncertainties in radiotherapy. The dosimetric and clinical 
benefits of modern high precision radiotherapy can be 
compromised by inaccurate delineation [Njeh CF. Med Phys 
2008]. Assurance of consistent and accurate contouring of the 
regions of interest is one of the main preconditions for safe 
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treatment delivery, optimal clinical outcome and meaningful 
reporting and comparison of treatments. 
In addition to high quality imaging and contouring guidelines, 
solid knowledge of radiological anatomy is a precondition to 
achieve best contouring standards. While this subject is 
recognized as one of the key competencies in the radiation 
oncology core curricula and training programmes [Eriksen JG, 
et al. Radiother Oncol 2012, www.acgme-i.org,], there is 
limited published data regarding the actual impact of the 
teaching interventions on contouring skills and the 
characteristics of the learning curve [Jaswal JK, et al. IJROBP 
2014, Cabrera AR, et al. J Am Coll Radiol 2011, Bekelman JE, 
et al. IJROBP 2009, D’Souza L, et al. BMC 2014]. 
Furthermore, published national surveys among radiation 
oncology residents and residency program directors indicate 
that there is room for improvement of training and 
evaluation of contouring competencies during residency [Jani 
AB, et al. Pract Rad Onc 2015, 12Jaswal JK, et al. IJROBP 
2013]. 
Contouring training should not be viewed as a process limited 
to the residency and fellowship programs and core-
curriculums. In a study evaluating the impact of prospective 
contouring rounds in a high volume academic centre, 36 % of 
cases required modification of contouring or written 
directives prior to treatment planning [Cox BW, et al. Pract 
Rad Onc 2015]. In a study of stereotactic body radiotherapy 
for lung cancer, the institutional peer-reviewers 
recommended major and minor changes of delineations in 23 
% and 37 % of 472 contoured structures, respectively [Lo AC, 
et al. J Thor Onc 2014]. In view of the rapid developments of 
imaging and radiotherapy delivery, accompanied by constant 
evolution and development of new contouring 
recommendations, the importance of continuous education of 
the experienced practitioners, mentors and trainers cannot 
be overemphasized. 
Research focusing on site-specific volumetric, topographic 
and qualitative aspects of contouring variation informs the 
educational activities in this field. The growing number of 
published inter-observer studies offers valuable resource to 
guide the training process. Limiting the learning to didactic 
and case-based instructions has improved knowledge scores 
and resident satisfaction in one study. However, this was not 
translated into improved contouring accuracy [D’Souza L, et 
al. BMC 2014]. In our experience, site-specific curriculum 
based on intensive sequence of didactic presentations, 
system-based instructions and hands-on contouring workshops 
represents an optimal strategy to achieve good learning 
results [Segedin B, et al. Submitted to Radiol Oncol 2016]. 
Feasibility and effectiveness of similar intensive educational 
interventions has been confirmed by others [Jaswal J, et al. 
IJROBP 2014]. 
These favourable early outcomes of teaching cannot be 
extrapolated on the long-term scale.Further evidence-based 
characterization of the learning curve is required to quantify 
the needs for continuous education and identify strategies for 
long term knowledge consolidation. Relative impact of the 
individual educational modules and qualifications of trainers 
on the learning outcome needs to be quantified, taking the 
tumour-site specific challenges into account. Development of 
training tools, including e-learning platforms and tools for 
objective assessment of contouring represent some of the 
main pre-requisites for future improvements in this field. 
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New physicists entering in to the speciality of brachytherapy 
normally undertake a formal training scheme in Medical 
Physics. Within the specialised field of brachytherapy the 
depth and breadth of training received can be dependent on 
the training scheme undertaken, training hospital’s expertise 
in brachytherapy, length of time dedicated to brachytherapy 
training and the assessment process.  
This presentation will summarise the key components of 
knowledge and experience a physicist should be expected to 
receive during their brachytherapy training and cross 
reference this to example training schemes. Several key 
questions need to be addressed when reviewing the training 
needs for image guided brachytherapy: Is additional training 
still required after completion of the formal training scheme? 
Are they appropriately focussed on image guided 
brachytherapy? 
It is important that any training gaps are identified and that 
measures are put in place to ensure that physicists have an 
understanding across all the components of image guided 
brachytherapy, have a full appreciation of the uncertainties 
and limitations within the brachytherapy pathway and of the 
systems used. 
Additional training resources will likely have to be explored 
to complement the core training schemes. Examples of 
available training resources will be presented and how they 
can potentially help facilitate the training and professional 
development of brachytherapy physicists. 
It is important that we ensure that opportunities for physicist 
training is not restricted and that physicists are allowed to 
develop their knowledge, understanding and skill set required 
for the modern image guided brachytherapy era. Training 
schemes need to continue to evolve and new training 
resources explored to complement formal training schemes 
and work based learning.  
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E-learning has the potential to deliver educational content to 
large numbers of learners world-wide. In 2008, Cook et al 
from the Mayo Clinic conducted a meta-analysis of 201 
studies of e-learning in the health professions. They found 
that internet-based instruction for medical professionals is 
associated with favorable outcomes across a wide variety of 
learners, learning contexts, clinical topics, and learning 
outcomes. Internet-based instruction appears to have a large 
effect compared with no intervention and appears to have an 
effectiveness similar to traditional methods. In a separate 
review in 2010, they identified that interactivity, practice 
exercises, repetition, and feedback improved learning 
outcomes.  
This talk discusses the potential of e-learning for teaching 
competency in target volume delineation (TVD). A crucial 
component of such a programme is automated assessment of 
contours with individualised feedback. The talk will compare 
conventional and novel methods for creating reference 
contours for TVD assessment, and conventional and novel 
metrics for automated assessment of TVD competency in 
individuals and groups of learners. The talk will also discuss 
the potential to investigate the impact of different 
instructional designs (e.g. live lectures, podcasts, annotated 
clinical cases, interactive demos) on TVD competency using 
quasi-experimental methodology. 
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A variety of therapeutic options are now available to cancer 
patients. It is recognised that significant biologic 
heterogeneity exists that may affect a patient’s likelihood of 
response to particular therapies and development of 
resistance on therapy. To be able to predict whether a 
patient will respond or not respond to a specific therapy is 
advantageous in streamlining patient management and 
minimising the costs of continuing therapy that is not working 
as well as minimising unwanted side-effects of such therapy.  
